Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Rinsho Ketsueki ; 50(8): 658-62, 2009 Aug.
Artigo em Japonês | MEDLINE | ID: mdl-19915381

RESUMO

We report a 79-year-old woman with T-cell prolymphocytic leukemia (T-PLL) who was successfully treated with fludarabine monophosphate. She was admitted to our hospital because of dyspnea on effort. On admission, anemia and hepatosplenomegaly were apparent but lymphadenopathy was absent. Peripheral blood examination showed anemia and leukocytosis with 29.5% abnormal lymphocytes. The bone marrow was infiltrated with 84.1% abnormal lymphocytes. The nucleolus was visible in some of these abnormal cells. These cells were positive for CD2, CD3, CD4, CD5, CD7, CD38, CD52, and negative for CD8, CD10, CD19, CD20, CD25, CD56. Based on these findings, she was diagnosed as having T-PLL. Therapy with oral cyclophosphamide (50 mg/day) was started, but was discontinued because of agranulocytosis. Then, she received intravenous fludarabine monophosphate (30 mg/day) on days 1-5 every four to five weeks. The reticulocyte count increased gradually, and she became free from red cell transfusions. Unfortunately, she finally died from massive gastro intestinal hemorrhage, but T-PLL was well controlled at the time of death.


Assuntos
Antimetabólitos Antineoplásicos/administração & dosagem , Leucemia Prolinfocítica de Células T/tratamento farmacológico , Fosfato de Vidarabina/análogos & derivados , Idoso , Esquema de Medicação , Evolução Fatal , Feminino , Hemorragia Gastrointestinal , Humanos , Infusões Intravenosas , Leucemia Prolinfocítica de Células T/sangue , Leucemia Prolinfocítica de Células T/diagnóstico , Leucemia Prolinfocítica de Células T/patologia , Resultado do Tratamento , Fosfato de Vidarabina/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA